Literature DB >> 15195260

Immunosuppression affects the severity of experimental Fusarium solani keratitis.

Tzu G Wu1, Victor V Keasler, Bradley M Mitchell, Kirk R Wilhelmus.   

Abstract

We have established a mouse model of corneal fusariosis that permits the evaluation of fungal infection and pathogenesis. Corneas of immunocompetent and cyclophosphamide-treated adult BALB/c mice were topically inoculated with Fusarium solani after corneal scarification. Eyes were scored for corneal involvement daily for 8 days and at 2 weeks after infection. Eyes were enucleated at various time points for quantitative fungal recovery and histopathological examination. An inoculum-dose response was observed in cyclophosphamide-treated mice, and fungi were recovered from the infected eyes by quantitative microbial culturing. Treatment with cyclophosphamide increased disease severity and delayed fungal clearance. Fungal hyphae, inflammatory cells, and stromal edema were histologically evident within corneal tissue and correlated with disease severity. Although the mouse cornea resists fungal infections, F. solani keratitis could be induced in immunosuppressed mice after surface scarification, which resulted in infection and clinical disease that could be evaluated both in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15195260     DOI: 10.1086/421300

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

Review 1.  The role of cytokines and pathogen recognition molecules in fungal keratitis - Insights from human disease and animal models.

Authors:  Sixto M Leal; Eric Pearlman
Journal:  Cytokine       Date:  2012-01-26       Impact factor: 3.861

2.  CXCL1/KC and CXCL5/LIX are selectively produced by corneal fibroblasts and mediate neutrophil infiltration to the corneal stroma in LPS keratitis.

Authors:  Michelle Lin; Eric Carlson; Eugenia Diaconu; Eric Pearlman
Journal:  J Leukoc Biol       Date:  2006-11-16       Impact factor: 4.962

3.  Time-dependent matrix metalloproteinases and tissue inhibitor of metalloproteinases expression change in fusarium solani keratitis.

Authors:  Qian Li; Xin-Rui Gao; Hong-Ping Cui; Li-Li Lang; Xiu-Wen Xie; Qun Chen
Journal:  Int J Ophthalmol       Date:  2016-04-18       Impact factor: 1.779

4.  Experimental model of Fusarium solani keratitis in rats.

Authors:  Jiang-Li Zhu; Xin-Rui Gao; Hong-Ping Cui; Li-Li Lang; Qian Li; Xin Liao
Journal:  Int J Ophthalmol       Date:  2011-08-18       Impact factor: 1.779

5.  The molecular pathogenicity of Fusarium keratitis: a fungal transcriptional regulator promotes hyphal penetration of the cornea.

Authors:  Xia Hua; Xiaoyong Yuan; Antonio Di Pietro; Kirk R Wilhelmus
Journal:  Cornea       Date:  2010-12       Impact factor: 2.651

6.  MyD88 regulation of Fusarium keratitis is dependent on TLR4 and IL-1R1 but not TLR2.

Authors:  Ahmad B Tarabishy; Bishr Aldabagh; Yan Sun; Yoshifumi Imamura; Pranab K Mukherjee; Jonathan H Lass; Mahmoud A Ghannoum; Eric Pearlman
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

7.  Toll-like receptors involved in the pathogenesis of experimental Candida albicans keratitis.

Authors:  Xiaoyong Yuan; Kirk R Wilhelmus
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-20       Impact factor: 4.799

8.  Protective role of murine β-defensins 3 and 4 and cathelin-related antimicrobial peptide in Fusarium solani keratitis.

Authors:  Satya Sree N Kolar; Hasna Baidouri; Samuel Hanlon; Alison M McDermott
Journal:  Infect Immun       Date:  2013-05-13       Impact factor: 3.441

9.  A murine model of contact lens-associated fusarium keratitis.

Authors:  Yan Sun; Jyotsna Chandra; Pranab Mukherjee; Loretta Szczotka-Flynn; Mahmoud A Ghannoum; Eric Pearlman
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-29       Impact factor: 4.799

10.  A fungal pH-responsive signaling pathway regulating Aspergillus adaptation and invasion into the cornea.

Authors:  Xia Hua; Xiaoyong Yuan; Kirk R Wilhelmus
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-22       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.